ON THE QUESTION OF THE SAFETY OF A 4-ALKYL-SUBSTITUTED COMPOUND WITH ANTI-TUMOUR ACTION-Reference-Cited by-同舟云学术

ON THE QUESTION OF THE SAFETY OF A 4-ALKYL-SUBSTITUTED COMPOUND WITH ANTI-TUMOUR ACTION

Published:2019-03-13 Issue:1 Volume:26 Page:101-107
ISSN:2541-9544
Container-title:Kuban Scientific Medical Bulletin
language:
Short-container-title:Kuban. nauсh. med. vestnik

Author:

Dudina Marina O.¹,Blinova Ekaterina V.¹,Moiseeva Inessa Ya.²,Samyshina Elena A.³,Suslova Irina R.¹,Blinov Dmitrii S.³

Affiliation:

1. I.M. Sechenov First Moscow State Medical University (Sechenov University)

2. Penza State University

3. Joint-stock company “All-Union Scientific Center for the Safety of Biologically Active Substances”

Publisher

Kuban State Medical University

Subject

General Medicine

Reference10 articles.

1. Seve P., Dumontet C. Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 2008; 9(2): 168–175. DOI: 10.1016/S1470-2045(08)70029-9

2. Fallah-Tafti A., Tiwari R., Shizari A.N. et al. 4-Aryl-4H-chromene-3-carbonitrile derivatives: evaluation of Src kinase inhibitory and anticancer activities. Med. Chem. 2011; 7(5): 466–472.

3. Patil S.A., Patil R., Pfeffer L.M., Miller D.D. Chromenes: potential new chemotherapeutic agents for cancer. Future Med. Chem. 2013; 5(14): 1647–1660. DOI: 10.4155/fmc.13.126

4. Bardashov I.N., Alekseeva A.U., Ershov O.V., Grishanov D.A. One-pot synthesis of 4-alkyl-2-amino4H-chromene derivatives. Heterocycl. Commun. 2015; 21(3): 175–177. DOI: 10.1515/hc-2015-0077

5. Arzamastsev E.V., Berezovskaya I.V., Verstakova O.L., Gus’kova T.A., Durnev A.D. Metodicheskie rekomendatsii po izucheniyu obshchetoksicheskogo deistviya lekarstvennykh sredstv. In.: Mironov A.N., ed. Rukovodstvo po doklinicheskomu izucheniyu lekarstvennykh sredstv. M.: Grif i Ko; 2012: 13–51 (in Russ.).